サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1720906

血栓性血小板減少性紫斑病（TTP）の世界市場レポート 2025年

Thrombotic Thrombocytopenic Purpura (TTP) Global Market Report 2025

出版日
ページ情報
英文 175 Pages
納期
2～10営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.90円
血栓性血小板減少性紫斑病（TTP）の世界市場レポート 2025年
出版日: 2025年05月01日
発行: The Business Research Company
ページ情報: 英文 175 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

血栓性血小板減少性紫斑病（TTP）の市場規模は、今後数年間で安定した成長が見込まれます。2029年には年間平均成長率（CAGR）4.7％で12億7,000万米ドルに成長します。予測期間の成長は、希少疾患研究への投資の増加、希少疾患治療への政府助成金の増加、希少疾患の診断におけるAIや機械学習の利用の拡大、高齢者人口の拡大、心血管疾患の有病率の上昇などに起因すると考えられます。この期間の主な動向には、疾患管理改善のための組換えADAMTS13酵素療法の開発、治療費削減のためのバイオシミラー医薬品の採用拡大、正確な診断のための次世代シーケンシングと高度な研究技術の使用、TTPの早期発見と他の血栓性疾患との鑑別のためのAIツールの導入、患者固有のプロファイルに基づく個別化治療アプローチの構築、希少疾患研究イニシアチブへの政府および民間部門の投資が含まれます。

心血管疾患の有病率の増加は、血栓性血小板減少性紫斑病（TTP）市場の成長を促進すると予想されます。心血管疾患には、冠動脈疾患、心不全、脳卒中など、心臓や血管に影響を及ぼすさまざまな疾患が含まれます。これらの疾患の増加は、高齢化、食生活の乱れ、運動不足、肥満、喫煙、過度のアルコール摂取、ストレスレベルの上昇などの要因と関連しています。血栓性血小板減少性紫斑病（TTP）は、広範な微小血管血栓症、内皮機能不全、全身性炎症を引き起こすことによって心血管問題を引き起こし、これらすべてが高血圧、心筋梗塞、その他の心血管合併症のリスクを高める。例えば、2023年12月、政府機関であるオーストラリア保健福祉研究所は、冠動脈性心疾患（CHD）による死亡者数が2021年の1万4,100人から2022年には1万4,900人に増加したと報告しました。この増加は心血管疾患の影響を浮き彫りにしており、TTP市場の成長を促進しています。

ヘルスケア支出の増加も血栓性血小板減少性紫斑病（TTP）市場を押し上げると予想されます。ヘルスケア支出とは、医療、病院サービス、予防医療、薬剤、調査、インフラ、管理費など、健康の改善や維持を目的とした医療サービスや製品への総支出を指します。高齢化、医療技術の進歩、慢性疾患の蔓延、ヘルスケアサービスに対する需要の高まりといった要因が、ヘルスケア支出の増加に寄与しています。このような支出は、高度な診断、血漿交換や免疫抑制療法などの救命治療、継続的な患者のモニタリング、新しい治療法の研究などへのアクセスを向上させ、最終的に患者の転帰を改善し合併症を減少させることで、TTP市場を支えています。例えば、2024年5月、英国政府機関である国家統計局は、英国のヘルスケア支出が2022年から2023年にかけて5.6％増加したと報告しました。英国のヘルスケア支出総額は、2023年には約3,176億3,000万米ドル（2,920億英ポンド）となりました。このヘルスケア支出の増加がTTP市場の成長に寄与しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症の影響と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

  • 世界血栓性血小板減少性紫斑病（TTP） PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
  • 最終用途産業の分析
  • 世界の血栓性血小板減少性紫斑病（TTP）市場：成長率分析
  • 世界の血栓性血小板減少性紫斑病（TTP）市場の実績：規模と成長, 2019-2024
  • 世界の血栓性血小板減少性紫斑病（TTP）市場の予測：規模と成長, 2024-2029, 2034F
  • 世界血栓性血小板減少性紫斑病（TTP）総アドレス可能市場（TAM）

第6章 市場セグメンテーション

  • 世界の血栓性血小板減少性紫斑病（TTP）市場：タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
  • 継承された血栓性血小板減少性紫斑病（TTP）
  • 血栓性血小板減少性紫斑病（TTP）を取得しました
  • 世界の血栓性血小板減少性紫斑病（TTP）市場治療別、実績と予測, 2019-2024, 2024-2029F, 2034F
  • 血漿交換
  • コルチコステロイド
  • リツキシマブ
  • カプラシズマブ
  • その他の治療の種類
  • 世界の血栓性血小板減少性紫斑病（TTP）市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
  • 病院
  • 専門センター
  • その他のエンドユーザー
  • 世界の血栓性血小板減少性紫斑病（TTP）市場遺伝性血栓性血小板減少性紫斑病（TTP）の病型別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
  • 先天性ADAMTS13欠損症
  • アップショー・シュルマン症候群
  • 世界の血栓性血小板減少性紫斑病（TTP）市場、後天性血栓性血小板減少性紫斑病（TTP）の病型別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
  • 免疫介在性TTP
  • セカンダリTTP

第7章 地域別・国別分析

  • 世界の血栓性血小板減少性紫斑病（TTP）市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
  • 世界の血栓性血小板減少性紫斑病（TTP）市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • 血栓性血小板減少性紫斑病（TTP）市場：競合情勢
  • 血栓性血小板減少性紫斑病（TTP）市場：企業プロファイル
    • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
    • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
    • Carelon Research Overview, Products and Services, Strategy and Financial Analysis
    • Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
    • Bristol Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

  • AstraZeneca
  • GlaxoSmithKline plc
  • Takeda Pharmaceutical Company
  • Amgen Inc.
  • Boehringer Ingelheim International GmbH
  • Teva Pharmaceutical Industries Ltd.
  • Baxter International Inc.
  • Astellas Pharma
  • Novartis AG
  • Eisai Co. Ltd.
  • Octapharma AG
  • Kite Pharma
  • Medscape
  • Omeros Corporation
  • Rigel Pharmaceuticals Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

  • 血栓性血小板減少性紫斑病（TTP）市場2029：新たな機会を提供する国
  • 血栓性血小板減少性紫斑病（TTP）市場2029：新たな機会を提供するセグメント
  • 血栓性血小板減少性紫斑病（TTP）市場2029：成長戦略
    • 市場動向に基づく戦略
    • 競合の戦略

第36章 付録

目次
Product Code: r34165

Thrombotic thrombocytopenic purpura (TTP) is a rare and life-threatening blood disorder that involves the formation of small blood clots (thrombi) within blood vessels throughout the body. These clots can obstruct blood flow to different organs, potentially causing organ damage. The primary treatment for TTP is plasmapheresis, which removes harmful antibodies and replaces the deficient ADAMTS13 enzyme.

The primary types of thrombotic thrombocytopenic purpura (TTP) are inherited and acquired TTP. Inherited TTP is a rare genetic condition caused by mutations in the ADAMTS13 gene, resulting in impaired breakdown of von Willebrand factor and recurrent clotting episodes. Treatment options for TTP include plasma exchange, corticosteroids, rituximab, caplacizumab, and other therapies. These treatments are used by a variety of end-users, such as hospitals, specialty centers, and other healthcare facilities.

The thrombotic thrombocytopenic purpura (TTP) market research report is one of a series of new reports from The Business Research Company that provides thrombotic thrombocytopenic purpura (TTP) market statistics, including the thrombotic thrombocytopenic purpura (TTP) industry global market size, regional shares, competitors with the thrombotic thrombocytopenic purpura (TTP) market share, detailed thrombotic thrombocytopenic purpura (TTP) market segments, market trends, and opportunities, and any further data you may need to thrive in the thrombotic thrombocytopenic purpura (TTP) industry. This thrombotic thrombocytopenic purpura (TTP) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The thrombotic thrombocytopenic purpura (TTP) market size has grown strongly in recent years. It will grow from $1.00 billion in 2024 to $1.05 billion in 2025 at a compound annual growth rate (CAGR) of 5.1%. The growth during the historic period can be attributed to increased awareness of rare blood disorders, a rising prevalence of autoimmune diseases associated with secondary TTP, advancements in immunosuppressive drug formulations, global growth in healthcare infrastructure, a stronger emphasis on patient education programs for chronic diseases, and the introduction of care guidelines for TTP by health organizations.

The thrombotic thrombocytopenic purpura (TTP) market size is expected to see steady growth in the next few years. It will grow to $1.27 billion in 2029 at a compound annual growth rate (CAGR) of 4.7%. The projected growth in the forecast period can be attributed to increased investment in rare disease research, higher government funding for rare disease treatments, growing use of AI and machine learning in diagnosing rare conditions, an expanding geriatric population, and a rising prevalence of cardiovascular diseases. Key trends during this period include the development of recombinant ADAMTS13 enzyme therapies for improved disease management, the growing adoption of biosimilar drugs to lower treatment costs, the use of next-generation sequencing and advanced lab techniques for accurate diagnosis, the implementation of AI tools for early detection of TTP and differentiation from other thrombotic disorders, the creation of individualized treatment approaches based on patient-specific profiles, and both government and private sector investments in rare disease research initiatives.

The increasing prevalence of cardiovascular diseases is expected to drive the growth of the thrombotic thrombocytopenic purpura (TTP) market. Cardiovascular diseases encompass a range of conditions affecting the heart and blood vessels, including coronary artery disease, heart failure, and stroke. The rise in these diseases is linked to factors such as an aging population, poor diets, lack of physical activity, obesity, smoking, excessive alcohol consumption, and higher stress levels. Thrombotic thrombocytopenic purpura (TTP) contributes to cardiovascular issues by causing widespread microvascular thrombosis, endothelial dysfunction, and systemic inflammation, all of which increase the risk of hypertension, myocardial infarction, and other cardiovascular complications. For example, in December 2023, the Australian Institute of Health and Welfare, a government agency, reported that deaths from coronary heart disease (CHD) rose to 14,900 in 2022, up from 14,100 in 2021. This increase highlights the impact of cardiovascular diseases, which is driving the growth of the TTP market.

The rise in healthcare spending is also expected to boost the thrombotic thrombocytopenic purpura (TTP) market. Healthcare spending refers to the total expenditure on health services and products, including medical care, hospital services, preventive care, medications, research, infrastructure, and administrative costs, all aimed at improving or maintaining health. Factors such as an aging population, advances in medical technology, the rising prevalence of chronic diseases, and greater demand for healthcare services contribute to higher healthcare spending. This spending supports the TTP market by enabling better access to advanced diagnostics, life-saving treatments such as plasma exchange and immunosuppressive therapy, ongoing patient monitoring, and research into new therapies, which ultimately improve patient outcomes and reduce complications. For instance, in May 2024, the Office for National Statistics, a UK government department, reported that healthcare spending in the UK increased by 5.6% between 2022 and 2023, compared to a 0.9% growth in 2022. The total healthcare expenditure in the UK was approximately $317.63 billion (£292 billion) in 2023. This rise in healthcare spending is contributing to the growth of the TTP market.

Companies in the TTP market are focusing on developing innovative therapies, such as recombinant enzyme replacement therapy, to improve treatment outcomes and efficacy. Recombinant enzyme replacement therapy involves administering synthetic or bioengineered enzymes to patients with enzyme deficiencies, restoring normal metabolic function. For example, in November 2023, Takeda Pharmaceutical Company Limited, a Japan-based company, introduced ADZYNMA, a recombinant ADAMTS13 enzyme replacement therapy that was approved by the U.S. Food and Drug Administration (FDA). This is the first and only treatment for congenital thrombotic thrombocytopenic purpura (cTTP) in both adult and pediatric patients. cTTP is a rare blood clotting disorder caused by a deficiency in the ADAMTS13 enzyme. Clinical trials supporting ADZYNMA's approval showed that the therapy effectively reduced the risk of acute TTP events, and it is now available in the U.S. for both prophylactic and on-demand treatment.

Major players in the thrombotic thrombocytopenic purpura (ttp) market are Pfizer Inc., Merck & Co. Inc., Carelon Research, Sanofi S.A., Bristol Myers Squibb Company, AstraZeneca, GlaxoSmithKline plc, Takeda Pharmaceutical Company, Amgen Inc., Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Baxter International Inc., Astellas Pharma, Novartis AG, Eisai Co. Ltd., Octapharma AG, Kite Pharma, Medscape, Omeros Corporation, Rigel Pharmaceuticals Inc.

North America was the largest region in the thrombotic thrombocytopenic purpura (TTP) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in thrombotic thrombocytopenic purpura (TTP) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the thrombotic thrombocytopenic purpura (TTP) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The thrombotic thrombocytopenic purpura (TTP) market consists of revenues earned by entities by providing services such as diagnostic services, immunosuppressive therapy, hospitalization & intensive care services, patient support programs, long-term management and follow-up care. The market value includes the value of related goods sold by the service provider or included within the service offering. The thrombotic thrombocytopenic purpura (TTP) market also includes sales of immunosuppressants, plasma-based therapies, monoclonal antibodies, and supportive care treatments. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Thrombotic Thrombocytopenic Purpura (TTP) Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on thrombotic thrombocytopenic purpura (ttp) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for thrombotic thrombocytopenic purpura (ttp) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The thrombotic thrombocytopenic purpura (ttp) market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Type: Inherited Thrombotic Thrombocytopenic Purpura (TTP); Acquired Thrombotic Thrombocytopenic Purpura (TTP)
  • 2) By Treatment: Plasma Exchange; Corticosteroids; Rituximab; Caplacizumab; Other Treatment Types
  • 3) By End-Users: Hospitals; Speciality Centres; Other End Users
  • Subsegments:
  • 1) By Inherited Thrombotic Thrombocytopenic Purpura (TTP): Congenital ADAMTS13 Deficiency; Upshaw-Schulman Syndrome
  • 2) By Acquired Thrombotic Thrombocytopenic Purpura (TTP): Immune-Mediated TTP; Secondary TTP
  • Companies Mentioned: Pfizer Inc.; Merck & Co. Inc.; Carelon Research; Sanofi S.A.; Bristol Myers Squibb Company
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Thrombotic Thrombocytopenic Purpura (TTP) Market Characteristics

3. Thrombotic Thrombocytopenic Purpura (TTP) Market Trends And Strategies

4. Thrombotic Thrombocytopenic Purpura (TTP) Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Thrombotic Thrombocytopenic Purpura (TTP) Growth Analysis And Strategic Analysis Framework

  • 5.1. Global Thrombotic Thrombocytopenic Purpura (TTP) PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 5.2. Analysis Of End Use Industries
  • 5.3. Global Thrombotic Thrombocytopenic Purpura (TTP) Market Growth Rate Analysis
  • 5.4. Global Thrombotic Thrombocytopenic Purpura (TTP) Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
  • 5.5. Global Thrombotic Thrombocytopenic Purpura (TTP) Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
  • 5.6. Global Thrombotic Thrombocytopenic Purpura (TTP) Total Addressable Market (TAM)

6. Thrombotic Thrombocytopenic Purpura (TTP) Market Segmentation

  • 6.1. Global Thrombotic Thrombocytopenic Purpura (TTP) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Inherited Thrombotic Thrombocytopenic Purpura (TTP)
  • Acquired Thrombotic Thrombocytopenic Purpura (TTP)
  • 6.2. Global Thrombotic Thrombocytopenic Purpura (TTP) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Plasma Exchange
  • Corticosteroids
  • Rituximab
  • Caplacizumab
  • Other Treatment Types
  • 6.3. Global Thrombotic Thrombocytopenic Purpura (TTP) Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hospitals
  • Speciality Centres
  • Other End Uers
  • 6.4. Global Thrombotic Thrombocytopenic Purpura (TTP) Market, Sub-Segmentation Of Inherited Thrombotic Thrombocytopenic Purpura (TTP), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Congenital ADAMTS13 Deficiency
  • Upshaw-Schulman Syndrome
  • 6.5. Global Thrombotic Thrombocytopenic Purpura (TTP) Market, Sub-Segmentation Of Acquired Thrombotic Thrombocytopenic Purpura (TTP), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Immune-Mediated TTP
  • Secondary TTP

7. Thrombotic Thrombocytopenic Purpura (TTP) Market Regional And Country Analysis

  • 7.1. Global Thrombotic Thrombocytopenic Purpura (TTP) Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 7.2. Global Thrombotic Thrombocytopenic Purpura (TTP) Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Thrombotic Thrombocytopenic Purpura (TTP) Market

  • 8.1. Asia-Pacific Thrombotic Thrombocytopenic Purpura (TTP) Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Thrombotic Thrombocytopenic Purpura (TTP) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.3. Asia-Pacific Thrombotic Thrombocytopenic Purpura (TTP) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.4. Asia-Pacific Thrombotic Thrombocytopenic Purpura (TTP) Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Thrombotic Thrombocytopenic Purpura (TTP) Market

  • 9.1. China Thrombotic Thrombocytopenic Purpura (TTP) Market Overview
  • 9.2. China Thrombotic Thrombocytopenic Purpura (TTP) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.3. China Thrombotic Thrombocytopenic Purpura (TTP) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.4. China Thrombotic Thrombocytopenic Purpura (TTP) Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Thrombotic Thrombocytopenic Purpura (TTP) Market

  • 10.1. India Thrombotic Thrombocytopenic Purpura (TTP) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.2. India Thrombotic Thrombocytopenic Purpura (TTP) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.3. India Thrombotic Thrombocytopenic Purpura (TTP) Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Thrombotic Thrombocytopenic Purpura (TTP) Market

  • 11.1. Japan Thrombotic Thrombocytopenic Purpura (TTP) Market Overview
  • 11.2. Japan Thrombotic Thrombocytopenic Purpura (TTP) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.3. Japan Thrombotic Thrombocytopenic Purpura (TTP) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.4. Japan Thrombotic Thrombocytopenic Purpura (TTP) Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Thrombotic Thrombocytopenic Purpura (TTP) Market

  • 12.1. Australia Thrombotic Thrombocytopenic Purpura (TTP) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.2. Australia Thrombotic Thrombocytopenic Purpura (TTP) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.3. Australia Thrombotic Thrombocytopenic Purpura (TTP) Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Thrombotic Thrombocytopenic Purpura (TTP) Market

  • 13.1. Indonesia Thrombotic Thrombocytopenic Purpura (TTP) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.2. Indonesia Thrombotic Thrombocytopenic Purpura (TTP) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.3. Indonesia Thrombotic Thrombocytopenic Purpura (TTP) Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Thrombotic Thrombocytopenic Purpura (TTP) Market

  • 14.1. South Korea Thrombotic Thrombocytopenic Purpura (TTP) Market Overview
  • 14.2. South Korea Thrombotic Thrombocytopenic Purpura (TTP) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.3. South Korea Thrombotic Thrombocytopenic Purpura (TTP) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.4. South Korea Thrombotic Thrombocytopenic Purpura (TTP) Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Thrombotic Thrombocytopenic Purpura (TTP) Market

  • 15.1. Western Europe Thrombotic Thrombocytopenic Purpura (TTP) Market Overview
  • 15.2. Western Europe Thrombotic Thrombocytopenic Purpura (TTP) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.3. Western Europe Thrombotic Thrombocytopenic Purpura (TTP) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.4. Western Europe Thrombotic Thrombocytopenic Purpura (TTP) Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Thrombotic Thrombocytopenic Purpura (TTP) Market

  • 16.1. UK Thrombotic Thrombocytopenic Purpura (TTP) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.2. UK Thrombotic Thrombocytopenic Purpura (TTP) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.3. UK Thrombotic Thrombocytopenic Purpura (TTP) Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Thrombotic Thrombocytopenic Purpura (TTP) Market

  • 17.1. Germany Thrombotic Thrombocytopenic Purpura (TTP) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.2. Germany Thrombotic Thrombocytopenic Purpura (TTP) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.3. Germany Thrombotic Thrombocytopenic Purpura (TTP) Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Thrombotic Thrombocytopenic Purpura (TTP) Market

  • 18.1. France Thrombotic Thrombocytopenic Purpura (TTP) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.2. France Thrombotic Thrombocytopenic Purpura (TTP) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.3. France Thrombotic Thrombocytopenic Purpura (TTP) Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Thrombotic Thrombocytopenic Purpura (TTP) Market

  • 19.1. Italy Thrombotic Thrombocytopenic Purpura (TTP) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.2. Italy Thrombotic Thrombocytopenic Purpura (TTP) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.3. Italy Thrombotic Thrombocytopenic Purpura (TTP) Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Thrombotic Thrombocytopenic Purpura (TTP) Market

  • 20.1. Spain Thrombotic Thrombocytopenic Purpura (TTP) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.2. Spain Thrombotic Thrombocytopenic Purpura (TTP) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.3. Spain Thrombotic Thrombocytopenic Purpura (TTP) Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Thrombotic Thrombocytopenic Purpura (TTP) Market

  • 21.1. Eastern Europe Thrombotic Thrombocytopenic Purpura (TTP) Market Overview
  • 21.2. Eastern Europe Thrombotic Thrombocytopenic Purpura (TTP) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.3. Eastern Europe Thrombotic Thrombocytopenic Purpura (TTP) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.4. Eastern Europe Thrombotic Thrombocytopenic Purpura (TTP) Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Thrombotic Thrombocytopenic Purpura (TTP) Market

  • 22.1. Russia Thrombotic Thrombocytopenic Purpura (TTP) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.2. Russia Thrombotic Thrombocytopenic Purpura (TTP) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.3. Russia Thrombotic Thrombocytopenic Purpura (TTP) Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Thrombotic Thrombocytopenic Purpura (TTP) Market

  • 23.1. North America Thrombotic Thrombocytopenic Purpura (TTP) Market Overview
  • 23.2. North America Thrombotic Thrombocytopenic Purpura (TTP) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.3. North America Thrombotic Thrombocytopenic Purpura (TTP) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.4. North America Thrombotic Thrombocytopenic Purpura (TTP) Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Thrombotic Thrombocytopenic Purpura (TTP) Market

  • 24.1. USA Thrombotic Thrombocytopenic Purpura (TTP) Market Overview
  • 24.2. USA Thrombotic Thrombocytopenic Purpura (TTP) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.3. USA Thrombotic Thrombocytopenic Purpura (TTP) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.4. USA Thrombotic Thrombocytopenic Purpura (TTP) Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Thrombotic Thrombocytopenic Purpura (TTP) Market

  • 25.1. Canada Thrombotic Thrombocytopenic Purpura (TTP) Market Overview
  • 25.2. Canada Thrombotic Thrombocytopenic Purpura (TTP) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.3. Canada Thrombotic Thrombocytopenic Purpura (TTP) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.4. Canada Thrombotic Thrombocytopenic Purpura (TTP) Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Thrombotic Thrombocytopenic Purpura (TTP) Market

  • 26.1. South America Thrombotic Thrombocytopenic Purpura (TTP) Market Overview
  • 26.2. South America Thrombotic Thrombocytopenic Purpura (TTP) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.3. South America Thrombotic Thrombocytopenic Purpura (TTP) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.4. South America Thrombotic Thrombocytopenic Purpura (TTP) Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Thrombotic Thrombocytopenic Purpura (TTP) Market

  • 27.1. Brazil Thrombotic Thrombocytopenic Purpura (TTP) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.2. Brazil Thrombotic Thrombocytopenic Purpura (TTP) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.3. Brazil Thrombotic Thrombocytopenic Purpura (TTP) Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Thrombotic Thrombocytopenic Purpura (TTP) Market

  • 28.1. Middle East Thrombotic Thrombocytopenic Purpura (TTP) Market Overview
  • 28.2. Middle East Thrombotic Thrombocytopenic Purpura (TTP) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.3. Middle East Thrombotic Thrombocytopenic Purpura (TTP) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.4. Middle East Thrombotic Thrombocytopenic Purpura (TTP) Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Thrombotic Thrombocytopenic Purpura (TTP) Market

  • 29.1. Africa Thrombotic Thrombocytopenic Purpura (TTP) Market Overview
  • 29.2. Africa Thrombotic Thrombocytopenic Purpura (TTP) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.3. Africa Thrombotic Thrombocytopenic Purpura (TTP) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.4. Africa Thrombotic Thrombocytopenic Purpura (TTP) Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Thrombotic Thrombocytopenic Purpura (TTP) Market Competitive Landscape And Company Profiles

  • 30.1. Thrombotic Thrombocytopenic Purpura (TTP) Market Competitive Landscape
  • 30.2. Thrombotic Thrombocytopenic Purpura (TTP) Market Company Profiles
    • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.2. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.3. Carelon Research Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.4. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.5. Bristol Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis

31. Thrombotic Thrombocytopenic Purpura (TTP) Market Other Major And Innovative Companies

  • 31.1. AstraZeneca
  • 31.2. GlaxoSmithKline plc
  • 31.3. Takeda Pharmaceutical Company
  • 31.4. Amgen Inc.
  • 31.5. Boehringer Ingelheim International GmbH
  • 31.6. Teva Pharmaceutical Industries Ltd.
  • 31.7. Baxter International Inc.
  • 31.8. Astellas Pharma
  • 31.9. Novartis AG
  • 31.10. Eisai Co. Ltd.
  • 31.11. Octapharma AG
  • 31.12. Kite Pharma
  • 31.13. Medscape
  • 31.14. Omeros Corporation
  • 31.15. Rigel Pharmaceuticals Inc.

32. Global Thrombotic Thrombocytopenic Purpura (TTP) Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Thrombotic Thrombocytopenic Purpura (TTP) Market

34. Recent Developments In The Thrombotic Thrombocytopenic Purpura (TTP) Market

35. Thrombotic Thrombocytopenic Purpura (TTP) Market High Potential Countries, Segments and Strategies

  • 35.1 Thrombotic Thrombocytopenic Purpura (TTP) Market In 2029 - Countries Offering Most New Opportunities
  • 35.2 Thrombotic Thrombocytopenic Purpura (TTP) Market In 2029 - Segments Offering Most New Opportunities
  • 35.3 Thrombotic Thrombocytopenic Purpura (TTP) Market In 2029 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer